Empire BlueCross

Precertification Required for Hemophilia Drugs

Empire BlueCross precertification requirements will change for certain hemophilia drugs. The 2015 Medicare Advantage list hemophilia drugs requiring precertification. As of July 1, 2015 providers must call for prior authorization of these drugs:

- C9136 Factor VIII, fc fusion protein, (recombinant)
- J7178 Human fibrinogen concentrate
- J7180 Factor XIII (antihemophilic factor, human)
- J7181 Factor XIII A-subunit, (recombinant), [Tretten]
- J7182 Factor VIII, (antihemophilic factor, recombinant), [Novoeight]
- J7183 Von Willebrand factor complex (human), Wilate
- J7185 Factor VIII (antihemophilic factor, recombinant) [Xyntha]
- J7186 Antihemophilic factor VIII/von Willebrand factor complex (human), per factor VIII IU [Alphanate]
- J7187 Von Willebrand factor complex [Humate-P]
- J7189 Factor VIIa (antihemophilic factor, recombinant)
- J7190 Factor VIII antihemophilic factor, human, [Hemofil M, Doate DVI, Monoclate-P]
- J7191 Factor VIII, antihemophilic factor [porcine]
- J7192 Factor VIII (antihemophilic factor, recombinant), [Advate, Helixate-FS, Kogenate-FS, Recombinate]
- J7193 Factor IX (antihemophilic factor, purified, non-recombinant) p [AlphaNine SD, Mononine]
- J7194 Factor IX complex, [Bebulin VH, Profilnine SD]
- J7195 Factor IX (antihemophilic factor, recombinant) ,[Benefix]
- J7198 Anti-inhibitor
- J7199 Hemophilia clotting factor, [Eloctate]
- J7200 Factor IX, (antihemophilic factor, recombinant), [Rixubis]
- J7201 Factor IX, Fc fusion protein (recombinant),

52703WPSENABC 03/25/15

Services provided by Empire HealthChoice HMO, Inc. and/or Empire HealthChoice Assurance, Inc., licensees of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association.
Empire BlueCross BlueShield

Precertification Required for Hemophilia Drugs

Empire BlueCross BlueShield precertification requirements will change for certain hemophilia
drugs. The 2015 Medicare Advantage list hemophilia drugs requiring precertification. As of July
1, 2015 providers must call for prior authorization of these drugs:

- C9136 Factor VIII, fc fusion protein, (recombinant)
- J7178 Human fibrinogen concentrate
- J7180 Factor XIII (antihemophilic factor, human)
- J7181 Factor XIII A-subunit, (recombinant), [Tretten]
- J7182 Factor VIII, (antihemophilic factor, recombinant), [Novoeight]
- J7183 Von Willebrand factor complex (human), Wilate
- J7185 Factor VIII (antihemophilic factor, recombinant) [Xyntha]
- J7186 Antihemophilic factor VIII/von Willebrand factor complex (human), per factor
  VIII IU [Alphanate]
- J7187 Von Willebrand factor complex [Humate-P]
- J7189 Factor VIIa (antihemophilic factor, recombinant)
- J7190 Factor VIII antihemophilic factor, human, [Hemofil M, Doate DVI, Monocluate-P]
- J7191 Factor VIII, antihemophilic factor [porcine]
- J7192 Factor VIII (antihemophilic factor, recombinant), [Advate, Helixate-FS, Kogenate-
  FS, Recombinate]
- J7193 Factor IX (antihemophilic factor, purified, non-recombinant) p [AlphaNine SD,
  Mononine]
- J7194 Factor IX complex, [Bebulin VH, Profilnine SD]
- J7195 Factor IX (antihemophilic factor, recombinant),[Benefix]
- J7198 Anti-inhibitor
- J7199 Hemophilia clotting factor, [Eloctate]
- J7200 Factor IX, (antihemophilic factor, recombinant), [Rixubis]
- J7201 Factor IX, Fc fusion protein (recombinant),

Services provided by Empire HealthChoice HMO, Inc. and/or Empire HealthChoice Assurance, Inc., licensees of the
Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. The Blue
Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association.